SCHEMBL4138311

SCHEMBL4138311

Cn1c(=O)[nH]c(N2CCN(C(c3ccccc3)c3ccccc3)CC2)c(Cc2ccccc2)c1=O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 11/20 0.72
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
HTR2A P28223 3/20 0.47
P2RX7 Q99572 3/20 0.46
CHRM2 P08172 2/20 0.44
ADORA3 P0DMS8 2/20 0.44
CYP2D6 P10635 2/20 0.44
CHRM1 P11229 2/20 0.44
CHRM3 P20309 2/20 0.44
HTR2C P28335 2/20 0.44
HRH1 P35367 2/20 0.44
OPRM1 P35372 2/20 0.44
DRD3 P35462 2/20 0.44
SLC6A3 Q01959 2/20 0.44
KCNH2 Q12809 2/20 0.44
MLNR O43193 1/20 0.44
NR1I2 O75469 1/20 0.44
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4151371 0.84 NR3C1 (1.00) NR3C1
SCHEMBL4151366 0.78 NR3C1 (1.00) NR3C1
SCHEMBL4147688 0.78 NR3C1 (1.00) NR3C1MEN1KMT2ALMNA
SCHEMBL4151367 0.76 NR3C1 (1.00) NR3C1OPRM1AVPR1AOPRK1
SCHEMBL4143729 0.76 NR3C1 (1.00) NR3C1
SCHEMBL4142930 0.75 NR3C1 (1.00) NR3C1
SCHEMBL4142917 0.74 NR3C1 (1.00) NR3C1HTR2AKCNH2
SCHEMBL4143690 0.73 NR3C1 (0.88) NR3C1MEN1KMT2ALMNASLC6A2
SCHEMBL4142900 0.70 NR3C1 (0.82) NR3C1MEN1KMT2ALMNA
SCHEMBL2672956 0.70 NR3C1 (0.59) NR3C1ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173664-B2 Modified pyrimidine glucocorticoid receptor modulators CORCEPT THERAPEUTICS, INC. (US) 2012-05-08 US disclosed
US-8173664-B2 Modified pyrimidine glucocorticoid receptor modulators CORCEPT THERAPEUTICS, INC. (US) 2012-05-08 US disclosed
US-20090275600-A1 MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS CORCEPT THERAPEUTICS, INC. (US) 2009-11-05 US disclosed
US-20090275600-A1 MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS CORCEPT THERAPEUTICS, INC. (US) 2009-11-05 US disclosed
US-7576076-B2 Modified pyrimidine glucocorticoid receptor modulators CORCEPT THERAPEUTICS, INC. (US) 2009-08-18 US disclosed
US-7576076-B2 Modified pyrimidine glucocorticoid receptor modulators CORCEPT THERAPEUTICS, INC. (US) 2009-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275600-A1 MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS NR3C1, NR3C2, TYMS NR3C1 1/4885MEN1 4371/4885KMT2A 2535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.